Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study

Fig. 5

Effects of acteoside and sorafenib on the tumor growth of BEL7404 HCC xenografts in mice. The BEL7404 cell suspensions were prepared (3 × 106 cells) and injected subcutaneously into the right flank of athymic nude mice. Fourteen days after the inoculation, tumor-bearing mice were treated via oral gavage with acteoside (A01; 12.5, 25 and 50 mg/kg), sorafenib alone (50 mg/kg) or in combination with A01 (50 mg/kg) once daily for 22 days. Tumor volume was measured twice a week. N = 5/group except for the model group (n = 8). Data are expressed as mean ± SEM. **,p < 0.01 vs the model group

Back to article page